[Systemic disease caused by the fungus Aspergillus fumigatus in immunocompromised patients]
Related Experiment Video
Updated: Oct 5, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
M Pospísil1, P Kessler, M Kheck
1Odd. klinické mikrobiologie Okresní nemocnice, Pelhrimov.
Abstract:
The authors describe an invasive pulmonary Aspergillus infection in three immunocompromised patients (1x plasmacytoma, 1x autoimmune thrombocytopenia, 1x asthma bronchiale) and draw attention to the possible occurrence of this disease also in subjects without serious neutropenia. The common risk factor in all three patients was corticoid treatment. In immunocompromised patients only early adequate and sufficiently long antimycotic treatment gives hope that the infection will be controlled.
Insights
Invasive pulmonary Aspergillus infection can occur in immunocompromised patients without severe neutropenia, particularly those on corticoid treatment. Early, adequate antifungal therapy is crucial for managing this serious fungal infection.
Area of Science:
- Pulmonology
- Infectious Diseases
- Mycology
Background:
- Invasive pulmonary Aspergillus infections are a significant concern in immunocompromised individuals.
- Risk factors typically include severe neutropenia, but other conditions may predispose patients.
Observation:
- This study details three cases of invasive pulmonary Aspergillus infection.
- Patients presented with conditions including plasmacytoma, autoimmune thrombocytopenia, and asthma bronchiale.
- Crucially, none of the patients had severe neutropenia.
Findings:
- Corticoid treatment was identified as a common risk factor across all three cases.
- The findings suggest that invasive pulmonary aspergillosis should be considered even in immunocompromised patients without neutropenia.
- Early and sufficient antifungal treatment is vital for successful disease control.
Implications:
- Highlights the importance of considering Aspergillus infection in a broader range of immunocompromised patients.
- Emphasizes the critical role of corticoids as a potential risk factor.
- Underscores the necessity of prompt and prolonged antimycotic therapy for better patient outcomes.
Related Concept Videos
Cryptococcal Meningitis
Fungal Phylum Ascomycota
Fungal Phylum Microsporidia
Fungal Group Zygomycota
Candidiasis
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
